CapsoVision Reports Slight Revenue Increase but Higher Net Loss in Q1 2026

CapsoVision, Inc. reported a slight increase in revenue for the first quarter of 2026, generating $2.79 million compared to $2.78 million in the same period last year. Despite this marginal growth, the company experienced a net loss of $7.03 million, a 31% increase from the $5.38 million loss reported in the prior year. The increase in losses was attributed to rising operating expenses, particularly in research and development, which surged by 43% to $4.44 million, driven by ongoing clinical trials and development costs associated with new products.

The company's total operating expenses rose to $8.42 million, up 22% from $6.88 million in the previous year. This increase was primarily due to higher selling and marketing costs, which grew by 7% to $2.09 million, and general and administrative expenses, which increased by 5% to $1.90 million. The gross profit for the quarter was $1.33 million, reflecting a gross margin of 48%, down from 54% in the same quarter of 2025, largely due to increased costs associated with customs and tariffs.

CapsoVision's operational metrics indicate a decrease in the number of CapsoCam Plus capsules sold, which fell by 3% year-over-year. However, the average selling price of these capsules increased by approximately 1%. International sales accounted for 28% of total revenue, up from 23% in the previous year, with significant contributions from markets in France and Germany. As of March 31, 2026, the company had cash and cash equivalents of $17.93 million, bolstered by a recent private placement that raised approximately $14 million.

Strategically, CapsoVision is focused on expanding its product offerings, particularly with the development of the CapsoCam Colon capsule, which is expected to enhance its market position in gastrointestinal diagnostics. The company is also investing in artificial intelligence capabilities to improve its existing products and streamline diagnostic processes. CapsoVision plans to submit a 510(k) application for its second-generation CapsoCam Colon capsule in the third quarter of 2026, following the completion of a pivotal clinical study.

Looking ahead, CapsoVision acknowledges the challenges it faces, including the need for additional capital to sustain operations and fund ongoing research and development. The company has expressed substantial doubt about its ability to continue as a going concern without further financing. Management is actively exploring various strategies to secure the necessary funding to support its growth initiatives and operational needs.